Accès ouvert
2026
other
OpenAlex
Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres
Table S6. Antibodies used for preclinical experiments
Accès ouvert
2026
other
OpenAlex
Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres
Table S4. Treatment-Emergent Adverse Events (≥3 patients) with PF-07799933 monotherapy and combination therapy
Accès ouvert
2026
other
OpenAlex
Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres
Figure S1. Preclinical characterization of PF-07799933 and comparison to other RAF inhibitors.
Accès ouvert
2026
other
OpenAlex
Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres
Table S5. Preliminary mutation analysis
Accès ouvert
2026
other
OpenAlex
Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres
Figure S3. Mouse plasma PK profiles for exarafenib and plixorafenib.
Accès ouvert
2026
other
OpenAlex
Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres
Table S2. X-ray crystallography data collection and refinement statistics
Accès ouvert
2026
other
OpenAlex
Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres
Table S3. Demographic and clinical characteristics of the patients
Accès ouvert
2026
other
OpenAlex
Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres
Figure S4. Patient PK profiles for PF-07799933.
Accès ouvert
2026
other
OpenAlex
Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres
Table S1. Cell lines used for cell-based pERK assays in Figure 1A
Accès ouvert
2026
other
OpenAlex
Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres
Figure S2. Crystal structures of BRAF kinase domain with PF-07799933 or encorafenib.
Accès ouvert
2026
other
OpenAlex
Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres
Figure S5. Efficacy for BRAF non-V600/Class II and Class III-mutant cancer patients.
Accès ouvert
2025
supplementary-materials
OpenAlex
Alexander Drilon, Melissa L. Johnson, Timothy A. Yap, Shirish M. Gadgeel et autres
Supplementary Data Title Page, Methods, References